Prognostic Factors Associated with Survival in Patients with Primary Duodenal Adenocarcinoma.
10.3904/kjim.2011.26.1.34
- Author:
Woo Chul CHUNG
1
;
Chang Nyol PAIK
;
Sung Hoon JUNG
;
Kang Moon LEE
;
Sang Woo KIM
;
U Im CHANG
;
Jin Mo YANG
Author Information
1. Department of Internal Medicine, The Catholic University of Korea School of Medicine, Seoul, Korea. cmcu@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Duodenal cacner;
Prognosis;
Cancer-directed treatment
- MeSH:
Adenocarcinoma/*mortality/pathology/therapy;
Adult;
Aged;
Aged, 80 and over;
Duodenal Neoplasms/*mortality/pathology/therapy;
Female;
Hospice Care;
Humans;
Male;
Middle Aged;
Neoplasm Staging;
Prognosis
- From:The Korean Journal of Internal Medicine
2011;26(1):34-40
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The prognostic factors in primary duodenal adenocarcinoma remain controversial. This study evaluated the prognostic factors associated with survival in patients with primary duodenal adenocarcinoma. METHODS: From March 1996 to June 2008, the medical records of 30 patients with a final diagnosis of primary duodenal epithelial malignancy seen at two referral centers were reviewed retrospectively. The prognostic factors for survival were evaluated 6 months and 1, 2, and 5 years after the diagnosis. RESULTS: The median survival was 5.7 months. The survival rate was 46.7% (14/30), 16.7% (5/30), 10% (3/30), and 6.7% (2/30) at 6 months and 1, 2, and 5 years, respectively. Multivariate analysis showed that cancer-directed treatment, including curative surgery or chemotherapy, was a common independent risk factor at all follow-up times. Total bilirubin, cytology, and TNM stage were independent risk factors for survival at 1, 2, and 5 years. The white blood cell count was an independent risk factor at 1 year only. The actuarial probability of survival in patients undergoing cancer-directed treatment was significantly higher than in those without treatment at 6 months (71.4 vs. 25.0%, p < 0.01), 1 year (28.6 vs. 6.3%, p < 0.01), 2 years (21.4 vs. 0%, p < 0.01), and 5 years (14.3 vs. 0%, p < 0.01). CONCLUSIONS: The prognostic factors in patients with primary duodenal adenocarcinoma were total bilirubin, TNM stage, cytology, and cancer-directed treatments until the 5-year follow-up. Especially, cancer-directed treatments improved patient survival.
